KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Inventory: 2020-2025

Historic Change in Inventory for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to -$1.7 million.

  • Aurinia Pharmaceuticals' Change in Inventory fell 1130.22% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of -$477,000 for FY2024, which is 103.01% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Change in Inventory of -$1.7 million as of Q3 2025, which was down 655.19% from $308,000 recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Change in Inventory high stood at $7.0 million for Q1 2023, and its period low was -$1.7 million during Q3 2025.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Change in Inventory value was $514,000 (recorded in 2024), while the average stood at $1.9 million.
  • Within the past 5 years, the most significant YoY rise in Aurinia Pharmaceuticals' Change in Inventory was 12,341.07% (2025), while the steepest drop was 1,130.22% (2025).
  • Aurinia Pharmaceuticals' Change in Inventory (Quarterly) stood at $278,000 in 2021, then soared by 120.86% to $614,000 in 2022, then spiked by 1,021.34% to $6.9 million in 2023, then tumbled by 92.53% to $514,000 in 2024, then plummeted by 1,130.22% to -$1.7 million in 2025.
  • Its Change in Inventory stands at -$1.7 million for Q3 2025, versus $308,000 for Q2 2025 and $7.0 million for Q1 2025.